The women’s health and wellness space is booming. The opportunities are real and so are the rewards. This is where you keep up. Welcome to The DXF Edit.
This Week’s Hot Topics:
- The federal government just bet $110 million on ending menopause as we know it.
- Hims & Hers is weeks away from becoming a global women’s health empire.
- Oura built an AI model that tracks 50+ biometric signals exclusively for the female body.
- Breast cancer survivors are still fighting their insurers in 2026. A bipartisan bill wants to change that.
- The 56-year-old program that gives low-income women access to birth control is being sabotaged.
- The Lululemon PFAS investigation might be less about your leggings and more about a Senate race.
MONEY MOVES
Menopause Is the Biggest Accelerant of Women’s Aging. Science Is Finally Coming For It.
The federal government just launched a $110 million Sprint for Women’s Health. Two of its biggest bets, Gameto and Celmatix, are going after something no therapeutic has ever touched: ovarian decline. The initiative is run by ARPA-H, the Advanced Research Projects Agency for Health.
Ovarian decline is the direct cause of menopause, and it doesn’t just cause hot flashes. It drives heart disease, dementia, osteoporosis, and metabolic disease in women. Right now, nothing on the market touches it at the source. Two companies are leading the charge to change that:
- Gameto received $10M to advance its Ameno program: a cell therapy approach using engineered ovarian support cells to extend ovarian function.
- Celmatix received $3.5M to develop a therapeutic targeting Anti-Müllerian Hormone, a key regulator of ovarian function previously considered undruggable.
Human trials are years away. And with federal funding under political pressure, ARPA-H’s runway is not guaranteed. But the ambition is real: for the first time, researchers are treating menopause at its source to improve the quality of life of all women long term.
Hims & Hers Is About to Go Global. Women’s Health Is the Play.
The $1.15 billion acquisition of Australian telehealth platform Eucalyptus is weeks away from closing, and the implications for women’s health are bigger than the headline.
Eucalyptus operates Juniper, a women’s weight loss clinic, and Kin, a reproductive healthcare platform. With these platforms, Hers would get a ready-made international women’s health infrastructure across Australia, Japan, the UK, Germany, and Canada. Hers already crossed 500,000 subscribers in the US and launched a menopause specialty this year with a stated target of $1B in revenue. The Eucalyptus deal accelerates that timeline globally.
The timing is pointed. Hims & Hers has been navigating US regulatory heat over compounded GLP-1s, and this acquisition is the clearest signal yet that the company is building beyond the American weight loss conversation.
The US is busy playing regulatory whack-a-mole with GLP-1s. Hims & Hers is busy building an empire.
INNOVATION
Oura Just Built the First AI Model Designed Exclusively Around the Female Body
On April 8, Oura launched its first proprietary large language model for women’s health, powering a new layer within Oura Advisor. For the women already devoted to the ring, this is a natural evolution of something they’ve trusted with their most intimate data.
That trust is well-earned. Women have been reporting for years that their ring flagged early signs of pregnancy up to nine days before a positive test, a pattern that UC San Diego researchers confirmed. When this went viral, Oura solidified its position in the wearables space for women. Oura’s user base is already 59% female, and its fastest-growing segment is women in their early twenties.
The new model builds on that foundation and covers the full reproductive spectrum. It interprets questions through 50+ biometric signals, temperature, HRV, sleep, stress, and cycle data. In a medical system where women feel dismissed, this can give them direct data to understand their bodies and possibly use at doctor’s visits.
One caveat: Oura has a commercial relationship with the Department of Defense using Palantir’s security infrastructure. Oura has been unequivocal that they never share consumer data, but that’s a policy decision the company can reverse at any time. The wall between your biometric data and a defense contractor is made of corporate promises, whatever those are worth.
Giving women more data on their bodies that they can share when they need is always a good thing, but that data has to be protected and solely controlled by the women owning it.
Scientists Just Shrunk the Human Cervix Down to the Size of a Thumb Drive
Millions of women are diagnosed with STIs every year. The models scientists have used to study them, cell cultures and mice, have never accurately reflected what actually happens inside the human cervix. Researchers just built one that does.
Published April 3 in Science Advances, a team from the Universities of Maryland, Delaware, and Virginia developed the world’s first immune-capable cervix-on-a-chip, a microphysiological system that realistically replicates the human cervical environment. The chip allows scientists to observe in real time how the microbiome, immune cells, and pathogens like chlamydia and gonorrhoea actually interact, something no cell culture or animal model has ever accurately replicated.
Nearly 1 million new STIs occur globally every day. Treatments have been slow to advance, partly because the research models have been inadequate.
One early finding is already striking: protective microbiomes dominated by Lactobacillus crispatus limited infection in the model, exactly as they do in women. Science is finally catching up to female biology, one chip at a time.
LAW & POLICY
Breast Cancer Survivors Are Still Fighting Their Insurance Companies. This Bill Wants to Change That.
More than 300,000 women are diagnosed with breast cancer in the US every year. They fight through diagnosis, surgery, and treatment. Then, too often, they have to fight their insurance company.
The Advancing Women’s Health Coverage Act would modernize the Women’s Health and Cancer Rights Act for the first time since 1998. That law required insurers to cover breast reconstruction after mastectomy. It hasn’t been updated in 27 years, while reconstructive medicine has moved on completely!
Insurance companies have exploited the outdated language to deny coverage for procedures that are now standard, advanced microsurgical techniques, tissue-based reconstruction, flat closure, custom prostheses, and lymphedema treatment. Roughly 30% of the time, surgeons can’t get modern reconstructive options covered. Up to 20% of breast cancer patients develop lymphedema, and many still can’t get adequate coverage for it.
The new bill closes those loopholes, covering every reconstruction modality under current medical coding, prohibiting minimum-only coverage, and requiring at least one in-network provider per option. In a political climate where women’s health legislation rarely earns bipartisan support, this one did.
Women shouldn’t be fighting their insurance company on top of everything else. This bill is LONG overdue!
Your Birth Control Is Caught in a Culture War. Again.
The Trump administration is quietly gutting Title X, the 56-year-old federal family planning program serving 2.8 million low-income Americans.
The administration’s new 2027 Title X guidelines shift the program’s focus from contraception to “natural family planning.” Natural fertility tracking and cycle awareness methods have pregnancy failure rates as high as 24% per year. The 70-page guidance mentions contraception only to call it overprescribed and harmful. It also instructs clinics to “end diversity, equity, and inclusion” and ensure funds aren’t used to “facilitate illegal immigration.” These are now the conditions for receiving family planning money.
The precedent is clear: during the first Trump administration, similar changes drove participation from 4 million patients to 1.5 million. For 2027, funding drops $29 million, from $286 million to $257 million.
Nine in ten Title X clients are women. The majority are under 30 and below the poverty line. For six in ten, it’s their only source of healthcare in a given year.
This is just another push in the efforts to increase birth rates. Not by providing women with structural support, not by reducing costs associated with bearing, birthing and raising a child, but by taking away resources that have given women choices. It transparently shows the lack of respect this administration has for women.
ON THE FEED
“Peptides” Is Just the New Word for Drugs Women Are Too Embarrassed to Say They’re Taking
Somewhere between the Ozempic backlash and the wellness influencer boom, a quiet rebranding happened. The drugs didn’t change. The word did.
Researchers tracking the trend say “peptides” became a deliberate alternative to “drugs”, softer, more scientific-sounding, and conveniently stigma-free. The tipping point was 2022, when GLP-1s exploded, and self-injecting became normalized.
Ozempic, Wegovy, and Mounjaro are FDA-approved, rigorously trialed, and well-understood peptides. The compounds flooding TikTok under names like BPC-157 and CJC-1295 are also peptides, but never tested in humans. They are largely sourced from Chinese labs, and technically illegal to sell for human use. One word for two very different things. That’s the issue.
Ozempic’s success created a halo effect: unproven compounds borrowing credibility from a drug that actually works. Two women nearly died at a Las Vegas wellness festival last year after receiving peptide injections. The pharmacy board couldn’t identify what was in the syringes. RFK Jr. has vowed to lift FDA restrictions on these peptides anyway.
“Peptides” is not a descriptive term for an established product. It’s a pharmaceutical term that got co-opted by an industry that needed a cleaner word.
The Lululemon PFAS Investigation Is Real. The Outrage Is Selective.
On April 13, Texas Attorney General Ken Paxton issued a Civil Investigative Demand to Lululemon over the potential presence of PFAS (“forever chemicals” linked to hormone disruption, infertility, thyroid disease, and certain cancers) in its activewear. Lululemon says it phased them out in early 2024 and is cooperating.
Independent lab testing has found PFAS in activewear from Nike, Athleta, Old Navy, and Vuori. Vuori acknowledged PFAS traces are common in repellent products and only tests against older-generation variants. Alo Yoga has made no public PFAS commitment and faces no investigation. Paxton picked one company out of an industry with a sector-wide problem.
Paxton is in a Senate primary runoff on May 26 against John Cornyn, with a documented pattern of launching high-profile consumer protection actions that generate headlines without requiring legislation. Lululemon, a brand synonymous with health-conscious women, is a visible target in an election cycle where MAHA sentiment runs high.
The federal contradiction is harder to ignore. On the same day Paxton launched the investigation, the Washington Post reported that the EPA was sitting on dozens of PFAS approvals out of fear of angering MAHA activists. The same EPA has been approving new PFAS-containing pesticides, rolling back PFAS drinking water standards, and moving to exempt 98% of businesses from PFAS reporting. RFK Jr.’s own former supporters are circulating petitions to fire EPA Administrator Zeldin. MAHA is the shiny brand. Harmful deregulation is the real policy.
31 state AGs in both parties are filling the federal gap. New York banned intentionally added PFAS in apparel as of January 2025. The leggings are the least of it.
THIS WEEK’S SELECTION
The INKEY List Exosome Hydro-Glow Complex — $34 Clinic-grade exosome technology, now in a $34 serum. Plant-derived exosomes clinically proven to improve radiance, firmness, and texture in 14 days.
Garmin + Natural Cycles — varies by Garmin device Wearable birth control, FDA-cleared. The most rigorous version of hormone-free fertility tracking available right now.
Creatine for Women — Momentous or Thorne — ~$25 Clinically confirmed to support muscle retention, cognitive performance, and mood in peri and menopausal women.
TOSLA Signaling Collagen Shot — new launch The first vegan signaling collagen in liquid form. Type 21 PrimaColl-powered, certified vegan, ready to drink.
Biodance Bio-Collagen Real Deep Mask Pack — ~$35 for 4 The K-beauty sheet mask taking over TikTok. A concentrated serum texture that delivers the glass skin it promises.
Barlean’s Omega-3 Fish Oil — Mango Peach — ~$22 Fish oil that actually tastes good. 1,080mg EPA and DHA plus Vitamin D3, wild-caught, mercury-free, burp-free.
The Ordinary Multi-Peptide Serum for Hair Density — $20 The hair growth serum that won’t break the bank. Editors saw above-average hair growth after eight weeks. Patience is required but the results are real!